Abstract:Background: Systemic therapy is the standard treatment for unresectable colorectal cancer with liver metastasis (CRCLM). Transarterial chemoembolization with drug-eluting beads (DEB-TACE) is considered an effective treatment option for CRCLM. Few studies have investigated the combination of DEB-TACE, chemotherapy, and targeted therapy for CRCLM. In the present study, we evaluated the disease control rate (DCR), adverse events, and survival among patients with CRCLM who underwent the combination of DEB-TACE and chemotherapy/targeted therapy. Materials: We retrospectively reviewed 35 patients with CRCLM who were treated between January 2015 and January 2021. Standard systemic chemotherapy, targeted therapy, and 66 DEB-TACE procedures were administered. Data were collected on each DEB-TACE procedure, including chemotherapy agents, tumor burden of liver metastasis, number of DEB-TACE courses, and adverse events. Patients who received DEB-TACE after failure of first-line systemic therapy were categorized into the first-line failure group. Patients who received DEB-TACE after the failure of second-line, third-line, or fourth-line therapy were categorized into the other group. Subgroup analysis was performed to compare overall survival (OS) and progression-free survival (PFS) between the two groups. Results: In total, 35 patients with CRCLM (34 patients with adenocarcinoma and 1 patient with neuroendocrine carcinoma) were enrolled. In total, 13 patients (37.1%) had extrahepatic metastases at initial diagnosis. In this study, 66 DEB-TACE procedures were performed. The DCR was 54.3%. The median OS period was 47.4 months, and the estimated 3-year OS rate was 59.5%. The median PFS period was 6.3 months, and the estimated 1-year PFS rate was 20.6%. The PFS period was longer in the first-line failure group than in the other group (7.2 vs. 6.3 months). No significant difference was observed in OS between the two groups. Four episodes (6.1%) of grade 3 intra-abdominal infection were observed. Conclusion: The combination of chemotherapy, targeted therapy, and DEB-TACE can lead to a favorable DCR and survival outcomes in patients with CRCLM. Early intervention with DEB-TACE (i.e., after the failure of first-line therapy) has the potential to extend the PFS period in patients with CRCLM. Severe adverse events were rare and manageable. Further prospective, randomized controlled studies are warranted to obtain more conclusive findings.

Efficacy and safety of raltitrexed-based transarterial chemoembolization for colorectal cancer liver metastases.

Safety and Tolerability Profile of Raltitrexed in Chinese Patients with Locally Advanced or Recurrent and Metastatic Colorectal Cancer: A Phase IV Trial.

[Evaluation of the Efficacy and Prognostic Factors for Colorectal Liver Metastases Treated with Transcatheter Arterial Chemoembolization].

Safety and tolerability of raltitrexed in patients with locally advanced recurrent and metastatic colorectal cancer:a phase Ⅳ trial

Transarterial Chemoembolization with Raltitrexed-Based or Floxuridine-Based Chemotherapy for Unresectable Colorectal Cancer Liver Metastasis

Efficacy and safety of irinotecan-eluting HepaSphere transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable colorectal liver metastases.

Transarterial chemoembolization of unresectable systemic chemotherapy‐refractory liver metastases from colorectal cancer: Long‐term results over a 10‐year period

A systematic review and meta-analysis on the efficacy and safety of transcatheter arterial chemoembolization combined with radiofrequency ablation in the treatment of primary liver cancer

Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post-transarterial chemoembolization for unresectable hepatocellular carcinoma

Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis.

The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

Efficacy of transarterial chemoembolization with drug-eluting beads combined with systemic chemotherapy and targeted therapy in colorectal cancer liver metastasis

Conventional Transarterial Chemoembolization Combined with Systemic Therapy Versus Systemic Therapy Alone As Second-Line Treatment for Unresectable Colorectal Liver Metastases: Randomized Clinical Trial.

Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Malignancy at High-risk ;Locations

Percutaneous Microwave Ablation Combined with Synchronous Transcatheter Arterial Chemoembolization for the Treatment of Colorectal Liver Metastases: Results from A Follow-Up Cohort

Efficacy of hepatic arterial infusion chemotherapy in patients with primary liver cancer with portal vein tumor thrombosis: a comparative analysis of different perfusion chemotherapeutic regimens

A randomized phase II trial of hepatic arterial infusion of oxaliplatin plus raltitrexed versus oxaliplatin plus 5-fluorouracil for unresectable colorectal cancer liver metastases

Radiofrequency ablation combined with transcatheter arterial chemoembolization for recurrent liver cancer

Radiofrequency Ablation Combined with Transarterial Chemoembolization for Treating of Hepatic Metastases

Oxaliplatin and 5-Fluorouracil Hepatic Infusion with Lipiodolized Chemoembolization in Large Hepatocellular Carcinoma.

Safety and efficacy of transcatheter arterial chemoembolization plus early sequential percutaneous radiofrequency ablation for the treatment of large primary liver cancer with hepatitis B cirrhosis:a single-center experience